Edition:
United Kingdom

G1 Therapeutics Inc (GTHX.OQ)

GTHX.OQ on NASDAQ Stock Exchange Global Select Market

50.91USD
18 May 2018
Change (% chg)

$2.60 (+5.38%)
Prev Close
$48.31
Open
$48.74
Day's High
$52.76
Day's Low
$48.74
Volume
63,343
Avg. Vol
71,223
52-wk High
$52.76
52-wk Low
$12.04

Select another date:

Thu, May 3 2018

BRIEF-G1 Therapeutics Reports Qtrly Loss Per Share Of $0.70

* G1 THERAPEUTICS PROVIDES FIRST QUARTER 2018 CORPORATE AND FINANCIAL UPDATE

BRIEF-G1 Therapeutics Files For Offering Of 3 Mln Shares

* FILES FOR OFFERING OF 3 MILLION SHARES OF ITS COMMON STOCK Source text: (http://bit.ly/2D2beLO) Further company coverage:

BRIEF-G1 Therapeutics Announces Positive Trilaciclib Phase 2A Topline Data Showing Robust Myelopreservation Benefits In Patients With Small Cell Lung Cancer

* G1 THERAPEUTICS ANNOUNCES POSITIVE TRILACICLIB PHASE 2A TOPLINE DATA SHOWING ROBUST MYELOPRESERVATION BENEFITS IN PATIENTS WITH SMALL CELL LUNG CANCER

BRIEF-G1 Therapeutics Qtrly Net Loss Per Share $0.60

* G1 THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS

BRIEF-Medimmune Ventures Sells 133,906 Shares Of G1 Therapeutics Inc's Common Stock On Dec 1

* MEDIMMUNE VENTURES INC REPORTS SALE OF 133,906 SHARES OF G1 THERAPEUTICS INC'S COMMON STOCK ON DEC 1 AT $19.75 PER SHARE - SEC FILING Source text: (http://bit.ly/2iVgOvs) Further company coverage:

BRIEF-G1 Therapeutics And AstraZeneca Enter Clinical Trial Collaboration In Non-Small Cell Lung Cancer

* G1 THERAPEUTICS AND ASTRAZENECA ENTER CLINICAL TRIAL COLLABORATION IN NON-SMALL CELL LUNG CANCER

Select another date: